Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 17/20 | 0.69 |
| ▸ | TACR3 | P29371 | 1/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401249 | 1.00 | TACR1 (0.69) | TACR1TACR3MITFCA1CA2 | |
| SCHEMBL1400972 | 1.00 | TACR1 (0.69) | TACR1TACR3MITFCA1CA2 | |
| SCHEMBL14098402 | 0.94 | TACR1 (0.67) | TACR1TACR3MITFCA1CA2 | |
| SCHEMBL14017628 | 0.91 | TACR1 (0.68) | TACR1TACR3MITFCA1CA2 | |
| SCHEMBL4819222 | 0.91 | TACR1 (0.68) | TACR1TACR3MITFCA1CA2 | |
| SCHEMBL4819217 | 0.91 | TACR1 (0.68) | TACR1TACR3MITFCA1CA2 | |
| SCHEMBL13871829 | 0.91 | TACR1 (0.62) | TACR1TACR3MITF | |
| SCHEMBL13818197 | 0.91 | TACR1 (0.62) | TACR1TACR3MITF | |
| SCHEMBL12809390 | 0.91 | TACR1 (0.65) | TACR1TACR3MITFCA1CA2 | |
| SCHEMBL13756721 | 0.89 | TACR1 (0.62) | TACR1TACR3MITFCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581518-B1 | SUBSTITUTED 1-PIPERIDIN-4-YL-4-PYRROLIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-02 | — | — | EP | disclosed |
| US-7795261-B2 | Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| US-7572786-B2 | Irritable bowel syndrome; tachykinin mediated condition such as schizophrenia, emesis, anxiety, depression, irritable bowel syndrome, circadian rhythm disturbances, pain, neurogenic inflammation, asthma, micturition disorder or nociception | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-08-11 | — | — | US | disclosed |
| US-7514424-B2 | Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-07 | — | — | US | disclosed |
| EP-1551804-B1 | SUBSTITUTED 1,4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-24 | — | — | EP | disclosed |
| US-7435736-B2 | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-10-14 | — | — | US | disclosed |
| US-7410970-B2 | Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-12 | — | — | US | disclosed |
| EP-1578744-B1 | SUBSTITUTED 4-(4-PIPERIDIN-4-YL-PIPERAZIN-1-YL)-AZEPANE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1578425-B1 | SUBSTITUTED 1-PIPERIDIN-3-YL-4-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2007-11-21 | — | — | EP | disclosed |
| US-20060167008-A1 | Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | ELANCO ANIMAL HEALTH IRELAND LIMITED (IE) | 2006-07-27 | — | — | US | disclosed |
| US-20060058285-A1 | Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-16 | — | — | US | disclosed |
| US-20060040950-A1 | Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | US | disclosed |
| EP-1578744-A1 | SUBSTITUTED 4-(4-PIPERIDIN-4-YL-PIPERAZIN-1-YL)-AZEPANE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-09-28 | — | — | EP | disclosed |
| EP-1578425-A1 | SUBSTITUTED 1-PIPERIDIN-3-YL-4-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-09-28 | — | — | EP | disclosed |
| EP-1551804-A1 | SUBSTITUTED 1,4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | Janssen Pharmaceutica N.V. (BE) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004110415-A2 | SUBSTITUTED 1, 4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVE COMBINED WITH AN OPIOID ANALGESIC AND THEIR USE FOR THE TREATMENT OF PAIN AND SIDE-EFFECTS ASSOCIATED WITH OPIOID-BASED TREATMENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004056805-A1 | SUBSTITUTED 4-(4-PIPERIDIN-4-YL-PIPERAZIN-1-YL)-AZEPANE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056772-A1 | SUBSTITUTED 1,4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056364-A1 | SUBSTITUTED 1-PIPERIDIN-3-YL-4-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004033428-A1 | SUBSTITUTED 1,4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167008-A1 | Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | NPSR1, VIP, TACR1 | TACR1 3/4885TACR3 575/4885MITF 3784/4885 |
| US-20060058285-A1 | Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists | NPSR1, TACR1, NPY1R | TACR1 2/4885TACR3 348/4885MITF 4338/4885 |
| US-20060040950-A1 | Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | NPSR1, TACR1, VIP | TACR1 2/4885TACR3 252/4885MITF 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.